The Epstein-Barr virus nuclear antigen 5 (EBNA-5) is encoded by highly spliced mRNA from the major IR1 (BamHI-W) repeat region of the virus genome. A mouse monoclonal antibody, JF186, has been raised against a synthetic 18-amino-acid peptide deduced from the EBNA-5 message of B95-8 and Raji cells. The antibody showed characteristic coarse nuclear granules by indirect immunofluorescence and revealed multiple EBNA-5 species by immunoblotting and immunoprecipitation. The B95-8 line itself and all B95-8 virus-carrying cells, whether lymphoblastoid cell lines or in vitro-converted sublines of Epstein-Barr virus (EBV)-negative Burkitt's lymphoma (BL) lines, were EBNA-5 positive. Among 36 cell lines carrying different EBV strains, only 10 expressed the B95-8-Raji-prototype EBNA-5 recognized by JF186; this was probably due to genetic variation in the epitope recognized by JF186, as shown for P3HR-1. Human antibodies, affinity purified against EBNA-5-JF186 immunoprecipitates, detected EBNA-5 in the majority of EBV-positive BL lines and in all lymphoblastoid cell lines containing the BL-derived viruses. Thus, EBNA-5 can be expressed by all virus isolates examined, but is down-regulated, together with other latent gene products, in a minority of BL lines which have a particular cellular phenotype. EBNA-5 was detected as a ladder of protein species of 20 to 130 kilodaltons (kDa), with a regular spacing of 6 to 8 kDa, consistent with the coding capacity of the combined BamHI-W 66-and 132-base-pair exons, together with shifts of 2 to 4 kDa, consistent with the size of the separate 66-and 132-base-pair exons. Multiple EBNA-5 proteins can be expressed by the single cell as shown by cloning of newly infected cells.
Epstein-Barr virus (EBV) is the causative agent of infectious mononucleosis (IM) and is closely associated with two malignancies, Burkitt's lymphoma (BL) and nasopharyngeal carcinoma. It is a highly efficient transforming agent for human B lymphocytes, leading to the establishment of continuously growing lymphoblastoid cell lines (LCLs). A family of EBV nuclear antigens (EBNAs) and a latent membrane antigen are expressed in growth-transformed cells (6a, 15) . Their analysis is crucially important for the understanding of the transformation process and the role of EBV in malignancy. The EBNA complex was originally defined by anticomplement fluorescence (24) and is expressed in every EBV-transformed cell. Recent analyses revealed that EBNA is a family of at least five proteins. Latent transcripts from the BamHI K and WYH regions code for EBNAs 1 and 2, respectively, whereas latent transcripts from the BamHI E region encode EBNA-3, EBNA-4, and EBNA-6 (5, 6a, 10, 11, 14, 31, 35, 36 ; A. Ricksten, B. Kallin, H. Alexander, J. Dillner, R. F?ahreaus, G. Klein, R. Lerner, and L. Rymo, Proc. Natl. Acad. Sci. USA, in press).
The BamHI WYH region is of particular interest since it is most probably involved in growth transformation; deletion of the EBNA-2-encoding part of the WYH region, as in the P3HR-1 and Daudi lines, is associated with the loss of transforming ability (13, 20, 23) . Studies on cDNA clones derived from the Raji (3), JY (34) , IB4 (32, 33) , and B95-8 (2, 4) cell lines have led to the identification of highly spliced transcripts, derived from the W fragment repeats, containing different numbers of 66-and 132-base-pair (bp) tandem exons. These cDNA data suggest the existence of a highly repetitive, arginine-and proline-rich protein of variable size encoded in addition to EBNA-2 in the BamHI WYH region. This protein may be encoded either by a separate message (33) or by polycistronic messages that also encode other latent proteins of the EBNA family (32) . The origin of the putative coding exons of EBNA-5 is summarized in Fig. 1 .
Using rabbit antisera raised to synthetic peptides corresponding to the W repeat exon, we have previously identified a protein of variable size which was designated EBNA-5 (7) . Recently, Wang et al. (38) have confirmed these findings using an affinity-purified human serum reagent obtained by reaction with a bacterial fusion protein expressing part of the EBNA-5 sequence. They designated the corresponding viral protein the leader protein, EBNA-LP, since it was encoded by a leader sequence of a bicistronic mRNA that also encoded EBNA-2 (32) . We continue to use the designation EBNA-5, because the possibility cannot be excluded that this protein is expressed independently of EBNA-2 and of other EBNAs.
To study more precisely the biology of EBNA-5, we have now raised a mouse monoclonal antibody (designated JF186) against the peptide 186 that was used in our previous study (7) . Because the 18-amino-acid peptide sequence (Pro-ArgGly-Asp-Arg-Ser-Glu-Gly-Pro-Gly-Pro-Thr-Arg-Pro-GlyPro-Pro-Gly) was deduced from the message corresponding to the BamHI-W repeats of B95-8 and Raji (3, 4) , we were derived by affinity purification of human serum reactive with EBNA-5-JF186 immunoprecipitates in order to detect other epitopes of the antigen. The monoclonal antibody proved to be useful to study a unique feature of EBNA-5, that is, the expression of multiple proteins from the same W repeat region.
MATERIALS AND METHODS
Cell lines. Cells were grown in RPMI 1640 (GIBCO Laboratories, Grand Island, N.Y.) supplemented with 10% heat-inactivated fetal calf serum, 2 mM glutamine, 25 ,ug of gentamicin per ml, 200 ,ug of streptomycin per ml, and 60 ,ug of penicillin per ml and were kept in a moist atmosphere with 5% CO2 at 370C. IARC-prefixed BL cell lines were kindly provided by G. Lenoir (18) , QIMR-prefixed lines were provided by D. Moss, and BL-postfixed cell lines and LCLs containing BL-derived EBV were provided by A. Rickinson (26, 27) . Cherry and SPIM lines (9) are spontaneous LCLs from the blood of IM patients; B95-8 is a marmoset cell line carrying IM-derived EBV (19) . PG N8652 was established from the blood of a patient with chronic lymphocytic leukemia by spontaneous outgrowth. The QIMR-WW1-LCL was an LCL immortalized by virus derived from the QIMR-WIL cell line (22) , and the CBC-SEB lines were derived by in vitro transformation of cord blood lymphocytes with EBV from throat washings of IM patients (9) . The BL lines presented in Table 1 have been characterized previously (9, 14, 27, 30, 30a Laemmli (17) . Electrophoretic transfer to nitrocellulose (Hybond C; Amersham Corp., Arlington Heights, Ill.) was done essentially as described by Towbin et al. (37) for 4 h at 14°C at 8 V/cm. The filters were stained with Ponceau S (Sigma), and the positions of the molecular weight markers (Bio-Rad Laboratories, Richmond, Calif.) were noted. After preabsorption in PBSM, the filters were incubated with hybridoma cell culture supernatants diluted 1:5 in PBSM overnight at 4°C. After three washes with PBSM, the filters were incubated with rabbit anti-mouse IgG (DAKOPATTS, Copenhagen, Denmark), 1:2,000, for 1 h, washed with PBSM and subsequently incubated with alkaline phosphatase-conjugated goat anti-rabbit IgG (Sigma) 1:1,000 in PBSM for 2 h at room temperature. The filters were washed six times with PBS-0.5% Tween 20 and stained with 50 mM Tris hydrochloride (pH 8.8)-2 mM MgCl2-0.2 mg of a-naphthylphosphate per ml-0.5 mg of Fast Red Salt (Sigma) per ml.
Immunoprecipitation. Cells (5 x 107) were disrupted by sonication (10 s on ice) in 1 ml of lysis buffer (0.5% sodium dodecyl sulfate 0.5% sodium desoxycholate, 0.5% Nonidet P-40, 150 mM NaCl, 50 mM Tris [pH 7.5], 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride). Lysates were incubated with 200 pul of monoclonal antibody hybridoma supernatant at 4°C by end-over-end rotation overnight before the addition of 50 pu1 of protein A-Sepharose CL-4B (Pharmacia, Uppsala, Sweden) for a further 4 h. The Sepharose beads were washed twice with lysis buffer and twice with PBS and were subsequently boiled in electrophoresis sample buffer.
Samples equivalent to material from 107 cells were used for immunoblotting as described above.
Purification of EBNA-5-specific human antibodies. EBNA-5 immunoprecipitates from 400 x 106 IB-4 cells were loaded onto a 16-cm-wide Laemmli gel for sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred to nitrocellulose as described above. Small strips from both edges of the nitrocellulose sheet were reacted with human serum from a chronic lymphocytic leukemia patient known to have high anti-EBNA titers in anticomplement IF (1:320). After immunostaining as described above but with goat antihuman IgG alkaline phosphatase-conjugated antibodies (Sigma), the developed strips were realigned with the original nitrocellulose sheet and a 1-cm-wide horizontal strip corresponding to the 42-kilodalton (kDa) EBNA-5 band of IB-4 was cut out and reacted with human serum, 1:20 in PBSM, for 2 h at room temperature. After four washes in PBS-0.5% Tween 20, the strip was placed in a plastic tube containing 1 ml of 500 mM diethylamine-150 mM NaCl, pH 11.5, for antibody elution (25) . After 2 min of gentle mixing, the strip was withdrawn and washed in PBS for reuse. The antibody-containing solution was neutralized with 0.2 M phosphate buffer, pH 2.0, and diluted 1:1 in PBSM for use in blotting or in PBS-10% fetal calf serum for IF.
IF. Air-dried cell smears were fixed with acetonemethanol 2:1 at -20°C for 5 min. After being washed in PBS, the smears were incubated with monoclonal antibody (1:20 dilution) for 1/2 h at room temperature in a moist chamber. Rabbit anti-mouse IgG fluorescein isothiocyanate conjugate (DAKOPATTS) diluted 1:10 in PBS was used as second antibody for 30 min at room temperature. Anticomplement IF, either with monoclonal antibody or with EBNA-reactive human sera, was done as described previously (24) .
Primary infection of B cells with B95-8 virus in vitro. High-density resting B cells were isolated from tonsils as described elsewhere (7) . The EBV-negative BL line Ramos was fed 24 h before the harvesting of cells for infection with B95-8 virus. Cells (3 x 107) were incubated for 2 h at 37°C with 40 ml of B95-8 cell culture supernatant. Cells were pelleted and suspended in fresh medium and distributed equally into three culture flasks. One flask was harvested every 24 h to test for EBNA-5, EBNA-1, and EBNA-2 expression by immunoblotting and by IF.
Cloning of B95-8-transformed B cells. Cloning was performed as described previously (8) . Ficoll-Isopaque-isolated cord blood lymphocytes were infected with EBV B95-8 at a low multiplicity of infection and subsequently were seeded in 96-well microculture plates with an average of 10 cells per well. Cells were fed weekly. After 4 to 6 weeks, growing clones were picked and transferred to culture flasks. The assay for EBNA-5 was performed 8 weeks after establishment. (Fig. 3) . The typical EBNA-5 size variation among different virus isolates (IB4, 42 kDa; Namalwa, 84 and 80 kDa; Jijoye, 35 kDa) as well as among different cell lines containing the same virus (P3HR-1, 20 kDa; EHR-ARamos, 90 and 82 kDa) was demonstrated with human anti-E5 (Fig. 3) . Table 1 To study the influence of the cellular phenotype on EBNA-5 expression, independent virus isolates carried by 20 BL cell lines were used to transform normal B cells as described previously (9, 26) . These BL-LCL pairs proved useful for study of the influence of the cellular phenotype on latent viral gene expression. The LCLs thus established invariably expressed EBNA-1, -2, -3, and -4, and latent membrane antigen, even when the BL cells from which the transforming virus was derived lacked expression of EBNA-2 and latent membrane antigen (29, 30a the same prototype transforming virus B95-8. All B95-8 virus-containing cell lines were found to express EBNA-5, usually as multiple bands in the form of a ladder, unlike the other EBNAs, which have a constant size for a given virus isolate ( Fig. 5; Table 2 ). EBNA-5 proteins varied in size between 20 kDa (BL41/95) and 130 kDa (E95-D-Ramos). Not all proteins of the ladder were expressed in every line, and the size of the predominantly expressed band as well as the overall expression level varied between different lines, irrespective of the BL versus LCL origin of the line. By analysis of the EBNA-5 proteins produced in several B95-8-carrying cell lines, it is clear that the spacing between the different EBNA-5 bands is more complex than the 6 kDa previously reported (7, 28) . The data shown in Table 2 are more consistent with the existence of three ladders, each having spacings of 6 to 8 kDa, superimposed upon each other.
Freshly infected cells and newly established lines generally expressed considerably more peptide species than longer established lines. Thus, the expression of multiple EBNA-5 proteins was particularly prominent after primary infection of resting B cells and the EBV-negative Ramos BL line (Fig. 6) . A 12-band EBNA-5 protein ladder, ranging between 20 and 119 kDa, appeared within 24 h of infection. The same ladder was expressed after primary infection both of normal B cells and of Ramos cells, but the signal intensity was much lower in Ramos cells, because a maximum of 10% of the Ramos cells became EBV positive, whereas the majority of the normal B cells became EBV positive. Parallel immunoblots probed with an EBNA-1-and EBNA-2-reactive human serum showed that EBNA-5 appeared coincidentally with EBNA-1 and -2 after infection of Ramos cells, whereas in tonsillar B cells, EBNA-5 appeared coincidentally with EBNA-2, and about 24 h earlier than EBNA-1 (data not shown).
To answer the question of whether each component of the EBNA-5 ladder was produced by a different cell within the general population, or whether a single cell was capable of producing several EBNA-5 species, cord blood cells were cloned by limiting dilution after transformation with B95-8 virus. The results shown in Fig. 7 demonstrate that different LCL clones differ in their predominant expression of particular EBNA-5-size species and that each clone contained multiple bands common to each other. These findings are also in line with the EBNA-5 ladder expression in the naturally monoclonal BL lines.
DISCUSSION
This report describes the generation of a monoclonal antibody, JF186, which is specific for EBNA-5 and which has allowed the expression of the viral protein to be studied in a wide panel of lines each carrying one of several strains of EBV. Using JF186 together with an EBNA-5-specific affinity-purified human serum, we have shown that all different virus isolates tested are capable of expressing EBNA-5 proteins, and we present evidence for EBNA-5 epitope variation among different EBV strains. In addition, the sensitive monoclonal antibody allowed the characterization of a much more complex and broader-ranging variation in the molecular size of the EBNA-5 proteins than was previously suspected (7, 28, 38) . Unexpectedly, a ladder of different-sized EBNA-5 proteins was demonstrated in monoclonal cell lines. These findings help to explain possible splicing mechanisms involved in the generation of this highly unusual viral protein. Cells  107  99  92  86   76   70  62  54  48  40  32  24   130  119  ---66  -50  42  34  28  20   ---84  75   68  60  52   44   38 (4) characterized several cDNA clones from B95-8. These transcripts contained variable numbers of W exons. Although these particular cDNAs represent a set of transcripts initiated in the BamHI C region and they do not contain the W01 exon required for the generation of the EBNA-5 initiation methionine codon (see Fig. 1 Analysis of the EBNA-5 ladder within and between different cell lines indicated that the spacing between the various EBNA-5 species is more complex than hitherto suspected. The predominant spacing of 6 to 8 kDa was confirmed and is consistent with the size of the combined W1-W2 exons. In addition, we observed shifts of 2 to 4 kDa, either as isolated bands or as separate superimposed ladders. The size of these shifts is consistent with the deletion of either of the Wl or W2 tandem exons (Fig. 1) as a result of alternative splicing. Support for this interpretation comes from the observation (4) that two cDNA clones (T2 and T6) lack a W2 exon in the W1-W2 repeat leader sequence. Thus, apart from the fact that different EBV strains contain various numbers of W repeats in their sequence, it has to be assumed that any number of combinations of the two exons alone or together can create reading frames with the capacity of proteins in the size range observed in this study, provided that a proper start codon is created by splicing of a 26-bp exon WO (providing nucleotides AT) to a 61-bp exon Wl (providing G) (33) .
The two cell lines P3HR-1 and Daudi, which both have a deletion in their genome within BamHI W, Y, and H fragments, express a low-molecular-weight EBNA-5 of 20 and 30 kDa, respectively. These cases demonstrate that EBNA-5 can be expressed independently of EBNA-2 and that the deletion of the C-terminal coding part in the BamHI W and Y fragments may affect the size but not automatically the stability of antigen expression. It is not clear where the EBNA-5 message terminates in these viruses. Conceivably, the EBNA-5 message could splice into another reading frame downstream from the BamHI-WYH deletion. Interestingly, EBNA-5 specific bands between 70 and 90 kDa could be seen in the cell line EHR-A-Ramos established by infection of EBV-negative Ramos cells with P3HR-1 virus (Fig. 3) .
The capacity of a single cell to produce multiple EBNA-5 gene products indicates a complex transcriptional mechanism in the major internal repeat of EBV. How, and under what circumstances, the various latent genes are transcribed and expressed independently or concomitantly remains to be further studied. In this respect, the availability of the sensitive monoclonal antibody described here should prove valuable.
